As HRSA's 340B Rebate Model Pilot moves toward its effective date, Valerie Bandy, PharmD, of Tecsys explains what drug-by-drug rebate tracking really demands from hospital and health system pharmacies.
|Articles|March 20, 2023
PAP 2023: Corey Ford Discusses Experience in Tackling Reimbursement Challenges at Access PAP 2023
AmerisourceBergen exec explains how his experience in health policy analysis and data analytics helps him tackle patient access obstacles.
Advertisement
In an interview with Pharma Commerce Editor, Nicholas Saraceno, Corey Ford, VP of reimbursement & policy insight, AmerisourceBergen, desribes his experience in combating reimbursement challenges at Access PAP 2023.
Advertisement
Related to this article
Episode 3 of Supply Chain Signal examines the Aug. 31 MFN agreements with nine mid-size manufacturers, the GENEROUS Medicaid model and whether pricing, trade and manufacturing policy now add up to a new pharma operating model.
Valerie Bandy of Tecsys on where 340B rebate mechanics threaten pharmacy purchasing, and how stakeholders can prevent disruption.
Rebate delays could force 340B hospitals to pay upfront and wait months for credit, distorting drug spend on the books. Valerie Bandy, PharmD, of Tecsys explains the fallout.
Inside the October 2026 issue: why splitting MMR takes years, why payers cite a price that does not bind them, and what pricing rules broke.
Patient support data that is trusted, connected and delivered into field workflows can move access teams from reporting to faster patient intervention.
Waltz Health and Fresenius Kabi will offer three biosimilars through a direct-to-payer model that bypasses traditional wholesaler and PBM rebate channels.
With HRSA's approval window now closed, attention turns to whether health system pharmacies can reconcile rebates at scale before the pilot's Jan. 1 start.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Cardinal Health, McKesson Extend CVS Distribution Deals to 2032
2
How Distribution Is Evolving for Today's Targeted Therapies
3
What to Watch at LogiPharma: Resilience, Practical AI and New Peer Formats
4
Your Patient Support Data Shows What Happened. Can It Tell You Why?
5